BioPharma Credit PLC STATEMENT RE EPIZYME (3676Q)
28 June 2022 - 4:00PM
UK Regulatory
TIDMBPCR
RNS Number : 3676Q
BioPharma Credit PLC
28 June 2022
28 June 2022
BIOPHARMA CREDIT PLC
(THE "COMPANY")
STATEMENT RE EPIZYME
Pharmakon Advisors, the Investment Manager of BioPharma Credit
PLC (the "Company") notes the announcement released yesterday by
Ipsen ("IPN") regarding the definitive agreement pursuant to which
Ipsen will acquire Epizyme Inc ("Epizyme") (the "Transaction"). The
Company has a US$110 million investment in a senior secured loan to
Epizyme which would be prepaid upon the closing of the Transaction.
The loan was made in four different tranches with each tranche
having a different prepayment economics. Depending on the actual
timing of the prepayment, the Company would be expected to receive
between US$3 to US$7 million in prepayment and make-whole fees.
Enquiries:
BioPharma Credit plc
via Link Company Matters Limited
Company Secretary
+44 (0)1392 477 500
Buchanan
David Rydell / Mark Court / Jamie Hooper / Henry Wilson
+44 (0)20 7466 5000
biopharmacredit@buchanan.uk.com
Notes to Editors:
BioPharma Credit PLC is London's only listed specialist investor
in debt from the life sciences industry and joined the LSE on 27
March 2017. The Company seeks to provide long-term shareholder
returns, principally in the form of sustainable income
distributions from exposure to the life sciences industry. The
Company seeks to achieve this objective primarily through
investments in debt assets secured by royalties or other cash flows
derived from the sales of approved life sciences products.
LEI: 213800AV55PYXAS7SY24
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com .
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy Policy
.
END
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCFRMRTMTMTBAT
(END) Dow Jones Newswires
June 28, 2022 02:00 ET (06:00 GMT)
Biopharma Credit (LSE:BPCP)
Historical Stock Chart
From Apr 2024 to May 2024
Biopharma Credit (LSE:BPCP)
Historical Stock Chart
From May 2023 to May 2024
